nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-CAB3878C·Framework v5.0·Pipeline v0.4·Evaluated 26 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Oncology·Basis: Full text·Type: Observational cohort study

Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy.

Sung et al.Sung, Son, Park et al.·2017·PloS one·10.1371/journal.pone.0173955 ↗

In brief

A competent retrospective prognostic study that adds combined pre/post-CRT NLR stratification, limited mainly by unvalidated data-derived cut-offs.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

PURPOSE: The neutrophil-lymphocyte ratio (NLR) has been suggested as an inflammation-related factor, but also as an indicator of systemic anti-tumor immunity. We aimed to evaluate the prognostic value of the NLR and to propose a proper cut-off value in patients with locally advanced rectal cancer who received preoperative chemoradiation (CRT) followed by curative total mesorectal excision (TME).

METHODS: A total of 110 rectal cancer patients with clinical T3-4 or node-positive disease were retrospectively analyzed. The NLR value before preoperative CRT (pre-CRT NLR) and the NLR value between preoperative CRT and surgery (post-CRT NLR) were obtained. Using a maximally selected log-rank test, cut-off values were determined as 1.75 for the pre-CRT NLR and 5.14 for the post-CRT NLR.

RESULTS: Patients were grouped as follows: group A, pre-CRT NLR ≤ 1.75 and post-CRT NLR ≤ 5.14 (n = 29); group B, pre-CRT NLR > 1.75 and post-CRT NLR ≤ 5.14, or pre-CRT NLR ≤ 1.75 and post-CRT NLR > 5.14 (n = 61); group C, pre-CRT NLR > 1.75 and post-CRT NLR > 5.14 (n = 20). The median follow-up time was 31.1 months. The 3-year disease-free survival (DFS) and overall survival (OS) rates showed significant differences between the NLR groups (3-year DFS rate: 92.7% vs. 73.0% vs. 47.3%, for group A, B, and C, respectively, p = 0.018; 3-year OS rate: 96.0% vs. 85.5% vs. 59.8%, p = 0.034). Multivariate analysis revealed that the NLR was an independent prognostic factor for DFS (p = 0.028).

CONCLUSION: Both the pre-CRT NLR and the post-CRT NLR have a predictive value for the prognosis of patients with locally advanced rectal cancer treated with preoperative CRT followed by curative TME and adjuvant chemotherapy. A persistently elevated post-CRT NLR may be an indicator of an increased risk of distant metastasis.

Strengths · Limitations

Strengths

#contribution

Clinically relevant prognostic-marker question

The study addresses heterogeneity in prognosis after preoperative CRT for locally advanced rectal cancer and asks whether pre- and post-treatment inflammatory markers can improve risk stratification. This is anchored in a treatment setting where the article states predictive markers are needed.

↳ Introduction, paragraph 1

#methodological rigour

Defined treatment and measurement timing

The methods specify CRT, surgery, adjuvant chemotherapy, and NLR measurement timing, including post-CRT NLR from CBC at four weeks after CRT. This supports interpretability of the prognostic timing relative to outcomes.

↳ Materials and Methods, Preoperative CRT; Surgery; Adjuvant Chemotherapy; NLR

#reporting

Clear survival-gradient presentation

The Results report a sequential decline in 3-year DFS and OS across NLR groups, with additional LRFS, DMFS, and failure-pattern reporting. The grouping scheme and outcome comparisons are presented in a way that makes the central association understandable.

↳ Results, DFS, LRFS, DMFS, OS, and failure patterns

#positioning

Relevant prior NLR literature engaged

The Discussion compares the study with earlier rectal-cancer NLR studies and explains why pre-CRT cut-off values varied across prior reports. This gives the incremental post-CRT and combined-marker claim a clear literature frame.

↳ Discussion, paragraphs on Carruthers, Nagasaki, and Shen studies

Limitations

#methodological rigour

Unvalidated outcome-derived NLR cut-offs

The cut-offs of 1.75 and 5.14 were selected using maximally selected log-rank testing with DFS in the same cohort used for prognostic evaluation. Without bootstrap, split-sample, or external validation, the apparent discrimination and exact thresholds are vulnerable to overfitting.

↳ Materials and Methods, Statistical Analyses; Results, NLR grouping and comparison between NLR groups

#methodological rigour

Small single-centre retrospective cohort

The analysis includes 110 patients from one hospital over 2006–2013, with a median follow-up of 31.1 months. This limits model stability, subgroup inference, and generalisability of the proposed grouping scheme.

↳ Materials and Methods, Patients; Results, DFS, LRFS, DMFS, OS, and failure patterns

#application pathway

Management implication exceeds evidence

The Discussion states that more aggressive adjuvant chemotherapy should be considered for group C, but the study is an observational prognostic analysis rather than a treatment-effect study. This limits the clinical-actionability of the finding.

↳ Discussion, paragraph on DMFS/systemic failure

#methodological rigour

Limited conduct transparency signals

The article declares institutional review board approval but provides no visible IRB identifier, conflict-of-interest statement, data availability statement, or code availability statement in the supplied text. These gaps affect inspectability rather than overturning the reported results.

↳ Materials and Methods, Patients; supplied full text overall

Does this match your read? Add your assessment ↓

Nabu Commentary

The adjudicated quality score is driven by a clear and clinically relevant retrospective prognostic analysis whose central NLR group gradient is reported consistently across DFS and OS. Methodological Rigour is held near the lower-middle range because the same dataset is used to select and test the NLR cut-offs, multivariable modelling relies on univariate screening and forward stepwise selection, and no validation analysis is reported. Contribution receives modest credit for adding post-CRT NLR and a combined grouping scheme to the rectal-cancer NLR literature, but the data-derived thresholds and single-centre design limit the strength of the advance. Impact potential is moderate-low: routine CBC measurement makes the idea practical, but the article does not provide externally validated cut-offs or a tested decision pathway for treatment or surveillance.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.1±0.2

Contribution
3.1

The paper adds an incremental but genuine prognostic-marker contribution by evaluating both pre-CRT and post-CRT NLR and combining them into a three-group stratification. The contribution is limited by its single-centre retrospective sample, short follow-up for some outcomes, and unvalidated data-derived thresholds.

Introduction, final paragraph; Results, NLR grouping and comparison between NLR groups; Discussion, paragraph claiming first study

"no report about evaluation of both the pre-CRT and post-CRT NLRs"

Methodological Rigour
2.8

The retrospective cohort design is appropriate for an initial prognostic association, with defined treatment protocols, NLR timing, endpoints, and Cox survival analyses. Methodological confidence is reduced by maximally selected same-dataset cut-offs, forward stepwise modelling, limited event counts, residual confounding, and no validation.

Materials and Methods, NLR; Materials and Methods, Statistical Analyses; Results, Clinicopathologic factors that influence DFS

"Multivariable models were derived using forward stepwise selection."

Reporting
3.8

The article presents the clinical rationale, methods, grouping scheme, survival outcomes, and limitations in a conventional and readable sequence. Reporting is reduced only modestly by occasional overstatement around optimal cut-offs and a minor p-value listing ambiguity in the univariate-results paragraph.

Abstract; Results, DFS, LRFS, DMFS, OS, and failure patterns; Discussion, limitations paragraph

"Further studies are needed to confirm the prognostic value"

Positioning
3.3

The paper situates the study within prior NLR work in solid tumours and rectal cancer, including studies using different pre-CRT cut-offs. It acknowledges small-sample, retrospective, and validation limitations, but does not fully contextualise the overfitting risk of outcome-derived thresholds.

Introduction, paragraphs 2–3; Discussion, prior NLR studies and limitations paragraphs

"the cut-off values for the NLR were variable"

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The paper is broadly internally consistent in sample counts, endpoints, and main survival results. Internal coherence is nevertheless noted because the same dataset is used to derive and evaluate NLR cut-offs, the Discussion calls these cut-offs optimal, and one treatment-intensification implication exceeds the retrospective prognostic design.

Research ConductNoted

Ethics approval is declared for the retrospective chart review, but no IRB identifier or corroborating detail is visible in the supplied article. No explicit conflict-of-interest, data-availability, code-availability, preregistration, or reporting-standard declaration is present.

Flags: 1 declared / 5 total

Reference IntegrityClean

All 36 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Colon and rectum cancer
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsFWCI 2.0
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The prognostic claim rests on a single-center retrospective cohort of 110 patients, with cut-off values derived and tested on the same data and no independent validation, which the authors themselves acknowledge.

From the paper
“especially in group C, careful evaluation of systemic failure is needed, and more aggressive adjuvant chemotherapy should be considered”

The paper names a real clinical use of its findings, risk-stratifying patients for more aggressive adjuvant chemotherapy, but does not specify who should act or in what decision setting.

Pathway

Oncologists managing locally advanced rectal cancer could use combined pre- and post-CRT NLR values to risk-stratify patients and intensify adjuvant chemotherapy or surveillance.

Barrier

The small retrospective single-center cohort and data-derived cut-offs require validation in large independent studies before the NLR groups can guide clinical decisions.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

    Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, et al. · 2023 · Clinical medicine

    Primary claim

    Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role.

    Supported
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  2. Osteonecrosis of the jaw associated with ziv-aflibercept

    Hani Mawardi, Peter Enzinger, Nadine J. McCleary, et al. · 2016 · Clinical medicine

    Evidence Score
    3.4±0.1
    Reliability
    Caveats
  3. Adjuvant Chemotherapy +/- Chemoradiotherapy for Adenocarcinoma of The Pancreatic Head: Results of The Radiotherapy Randomization of NRG Oncology/RTOG 0848

    Ross A Abrams, Kathryn Winter, Karyn A. Goodman, et al. · 2026 · Clinical medicine

    Evidence Score
    3.9±0.1
    Reliability
    Concerns

How the rubric works →